

The Effect of Metformin Therapy on Clomiphene Citrate-resistant Polycystic Ovarian Syndrome Women

Sang Hyeon Ko, Sang Hoon Lee

Department of Obstetrics and Gynecology, College of Medicine,
Chung-Ang University, Seoul, Korea

Objective: This study was performed to investigate the effect of metformin therapy on ovulation induction & pregnancy rate in clomiphene citrate-resistant PCOS women.

Method: This study used a randomized, single-blinded, case-controlled methods. Total study group consisted of 21 women who showed clomiphene citrate-resistant pattern on previous ovulation induction cycles. Patients of metformin group received metformin 500 mg three times daily, for 7 weeks. Control group received none. Metformin group was consisted of 10 women and control group was consisted of 11 women. Then clomiphene was administered at daily 50 mg for 5 days to both groups. Clomiphene dosage was increased to daily 150 mg until ovulation was occurred. Before and After metformin treatment, blood samples for measurement of insulin, glucose, steroids were obtained.

Results: In the metformin and control groups, 6 of 10 women (60%) and 2 of 11 women (18%) ovulated. And 4 of 10 women (40%) and 0 of 11 women (0%) conceived. Comparisons between the groups were significant.

Conclusion: In PCOS women who are resistant to CC, metformin use increased the ovulation rate and pregnancy rate from CC treatment, significantly.

Key Words: Metformin, Insulin resistance, Polycystic ovarian syndrome

PCOS) (Polycystic ovarian syndrome, tance) (Compensa-
(chronic anovulation) tory hyperinsulinemia)
(hyperandrogenism) 1 2-9

(Insulin resis-

: , 271 82-1,
Tel: (02) 2260-2187, Fax: (02) 6263-2187, e-mail: dreamsky3@freechal.com

¹⁰
 가 가 , 가
 (Insulin-like Growth Factor, IGF)
 (folliculogenesis)
¹¹
¹²
 2
 (insulin sensitizing drug) troglitazone
 (metformin)
^{8,9,17}
 (Clomiphene citrate,), troglitazone
 hMG, pure-FSH, GnRH-agonist .
 70% 50 mg 100 mg . 1994 Velazquez
¹³
 250 mg 150 mg .
 nide .
¹⁷
 가
¹⁴
 가
¹⁵
 가
 (Ovarian hyperstimulation syndrome, OHSS)
 가
 hMG FSH

1.

2000 10 2001 6

9 75 g
60 , 120 ,
10 ,
21 11 7
18~35 75~98 kg 가
가
500 mg 3
(Progesterone
LH/FSH free or total testosterone, androstenedione, DHEA-sulfate 가 level > 4 ng/mL) 10, 20,
30, 40
7
가,
가 (hypercortisolism) 5 50 mg
(congenital adrenal hyperplasia, CAH) 21 28 progesterone
50 mg 가 150 mg
가 6
50 mg 가 150 mg
150 mg 5
5
가 progesterone
1
TSH, Prolactin, 17-hydroxyprogesterone (< 200 ng/dL)
lactic acidosis 가
(serum creatinine concentration < 1.4 mg/dL) 가
가

randomized, single-blinded, case-controlled

2.

3.

12 8 Student's t-test Fisher exact test
, p 0.05
(Body Mass Index, BMI), Waist-hip ratio 가
8:30, 8:45, 9:00 insulin, glucose,
17-hydroxyprogesterone, total and free T, androstenedione, DHEA-sulfate, E₂, estrone, LH, FSH, SHBG

Table 1. Characteristics and biochemical markers of Clomiphene Citrate-resistant PCOS women before and after 7 weeks of treatment with metformin or placebo

Characteristics	Metformin Group (n=10)		Control Group (n=11)		P-value
	Baseline	After Tx	Baseline	After Tx	
Age (years)	28.2 ±1.4		29.3 ±1.3		
Weight (kg)	64.3 ±5.4	65.3 ±7.2	65.4 ±5.4	66.3 ±6.3	NS
BMI (kg/m ²)	35.4 ±3.8	34.2 ±4.3	37.2 ±4.3	37.5 ±5.2	NS
Fasting plasma insulin level (mU/ml)	7.8 ±1.4	8.4 ±2.1	8.2 ±1.5	8.5 ±1.7	NS
Fasting glucose level (mg/dL)	83.2 ±2.4	81.2 ±1.8	84.2 ±2.6	85.3 ±2.2	NS
Serum free T level (pmol/L)	6.6 ±0.4	6.2 ±0.6	6.8 ±0.7	6.5 ±0.4	NS
Serum androstenedione level (ng/mL)	2.3 ±0.25	2.1 ±0.18	2.0 ±0.17	2.1 ±0.16	NS
Serum E ₂ level (pg/mL)	25.3 ±3.5	24.3 ±4.7	24.7 ±3.2	26.4 ±4.1	NS
Serum DHEAS level (ug/dL)	12.4 ±1.5	13.1 ±2.1	13.2 ±2.2	14.2 ±1.8	NS
Serum LH level (mIU/mL)	4.5 ±0.25	4.8 ±0.17	5.3 ±0.45	5.6 ±0.38	NS
Serum FSH level (mIU/mL)	198 ±24.6	204 ±18.7	203 ±21.3	187 ±34.2	NS
Serum progesterone level (ng/mL)	1.2 ±0.89	2.0 ±0.67	0.98 ±0.07	1.6 ±0.12	NS

NS: not significant

Table 2. Ovulatory and pregnancy outcomes in response to clomiphene citrate in both groups

Outcome	Metformin Group (n=10)	Control Group (n=11)	P value
No. of women who ovulated/total no. of women	6/10	2/11	<0.05
No. of women who ovulated (%)	60%	18.1%	<0.05
No. of women who conceived/total no. of women	4/10	0/11	<0.05
No. of women who conceived (%)	40%	0%	<0.05

testosterone, androstenedione, E₂, LH,

FSH, DHEA-S

28.2 29.3
64.3 kg, 65.3 kg, 66.3 kg (Table 1).
65.4 kg 가
35.4 kg/ 37.2 kg/m² 34.2 kg/m², 37.5 kg/m² 18%
37.2 kg/m² 34.2 kg/m², 37.5 kg/m² 18%
10 6 60%
4 40%
11 2
0%
가 (Table 2).

10

Table 3. Ovulatory response to treatment with metformin and clomiphene citrate in Metformin group (n=10)

Patients	No. of ovulatory cycles	Pregnancy achieved
1	3	Yes
2	0	No
3	1	No
4	2	Yes
5	0	No
6	2	Yes
7	0	No
8	5	Yes
9	3	Yes
10	2	Yes

1980 Burghen

25

가

가

가

6 가 2 1
 5 가 3 2
 1 3
 (Table 3).
 21

(central obesity)

10

가

가

26

가

가

가

27

rum)

(spect-
subset
(non-

obese, non-obese)

가

non-obese

가

가

21,22

-I (insulin-like growth factor-I, IGF-I) 가,
(insulin-like

growth factor binding protein, IGFBP)

가

28 IGF (IGF system) IGF

23,24

IGF

(IGF-bin-

ding protein, IGFBP) IGF
 (intraovarian regulating growth factor)
 가 .²⁷ IGF
 IGF-I IGF-II 가 ,
 .¹¹
 가
 (insulin receptor dis- , hMG, pFSH 가 ³¹
 order) GnRH-agonist
 . 1961 Greenblatt
 (peripheral insulin re-
 sistance)
 가
 가
 IGF-I dexamethasone
 .^{29,30}
 IGF-I .³² 5
 (CC failure)
 IGF-I
 가
 가
 가 IGF-I
 , OHSS
 ,¹⁶
 disul-
 fide bond α - β dimer hetero 가 OHSS
 rotetramer α -subunit ligand-
 binding domain β -subunit 가,
 가 protein tyro-
 sine kinase ligand-medi-
 ated autophosphorylation .
 IGF-I protein tyrosine
 kinase IGF-I 15 ,
 substantial sequence (ho-
 mology) 가 cross-over
 .¹¹ (sensitizer) 가
 가
 가

troglitazone metformin
 Troglitazone
 가 .35-39
 5 1 가 Ma-
 1957 biguanide .
 (antihyperglycemic) 2 .12
 가
 postre-
 ceptor level (insulin sensitivity) (masking)
 가 insulin-mediated glucose disposal
 (stimulation) .33
 1.7~4.5 가 David
 lactate PCOS
 . 3 8 32
 lactic acidosis가 3
 가 .34
 testosterone , kg/m²
 가 OHSS non-obese
 500 mg 3 가
 tolerance 500 mg 가
 1 1 1 2 2
 3
 가 850 mg 가 .
 2 가 7 1
 .34
 500 mg 3 7 가
 가

가 .

가

David
32

가

가

(IVF-ET)

가

OHSS 가

non-
obese

가

1. Knochenbauor ES, Key TJ, Kabsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States; a prospective study. *J Clin Endocrinol Metab* 1998;

03: 3078-82.

2. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J Clin Endocrinol Metab* 2000; 85: 139-46.

3. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. *Fertil Steril* 1999; 72: 282-5.

4. Gleuck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. *Metabolism* 1999; 48: 511-9.

5. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. *Fertil Steril* 1999; 71: 323-7.

6. Nestler JE, Jakubowicz DJ, Reamer P, Gunn R, Allan G. Ovulatory and metabolic effects of dchiro-inositol in the polycystic ovary syndrome. *N Engl J Med* 1999; 340: 1314-20.

7. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. *Fertil Steril* 1998; 69: 691-6.

8. Nestler JE, Jakubowicz DJ, Evans WS, Psaquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. *N Engl J Med* 1998; 338: 1876-80.

9. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. *Obstet Gynecol* 1997; 90: 392-5.

10. . 44
3 , 302-13, 2001 .

11. Dunaif A. Insulin resistance and the polycystic

- ovary syndrome: Mechanism and Implications for pathogenesis. *Endocrine Reviews* 1997; 18(6): 774-800.
12. Maria JJ, John EN. The polycystic ovary syndrome: treatment with insulin sensitizing agents. *Diabetes, Obesity and Metabolism* 1999; 1: 127-36.
 13. Gysler MG, March CM, Mishell DR, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. *Fertil Steril* 1982; 37: 161-7.
 14. Lobo RA, Gysler M, March CM, Goebelsmann U, Mishell DR. Clinical and laboratory predictors of clomiphene response. *Fertil Steril* 1982; 37: 168-74.
 15. Murafawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. *J Reprod Med* 1999; 44: 23-7.
 16. Chung-hoon Kim, Hee-dong C, Eun-hee K, Hyung-sik C, Byung-moon K, Yoon -seok C. The effects of somatostatin analogue on ovarian response to ovulation induction in patients with polycystic ovarian syndrome. 1999; 42(3): 496-503.
 17. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic pressure, while facilitating normal menses and pregnancy. *Metabolism* 1994; 43: 647-54.
 18. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhani S, Quiason SG, Phillips NJ, et al. Troglitazone induced hepatic failure leading to liver transplantation. *Ann Intern Med* 1999; 130: 163-4.
 19. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. *Diabetes Care* 1993; 16: 621-9.
 20. DeFronzo RA, Barzilai N, Smonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. *J Clin Endocrinol Metab* 1991; 73: 1294-301.
 21. Hoff JD, Lasley BL, Yen SSC. The functional relationship between priming and releasing actions of luteinizing hormone-releasing hormone. *J Clin Endocrinol Metab* 1979; 49: 8-15.
 22. Yen SSC. The polycystic ovarian disease. *Clin Endocrinol (Oxford)* 1980; 12: 177-207.
 23. Yen SSC, Jaffe RB. *Reproduction*. Endocrinology 3rd Ed, Philadelphia, WB Saunders 1991; 593-7.
 24. Falcone T, Bourque J, Granger L, Hemmings R, Miron P. Polycystic ovary syndrome. *Current Problems Obstet Gynecol Fertil* 1993; 16: 72-89.
 25. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. *J Clin Endocrinol Metab* 1980; 50: 113-6.
 26. Smith S, Ravnkar VA, Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. *Fertil Steril* 1987; 48: 72-7.
 27. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. *Fertil Steril* 1988; 50: 197-212.
 28. Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. *Am J Obstet Gynecol* 1983; 147: 588-92.
 29. Dunaif A, Hoffman AR. Insulin resistance and hyperandrogenism: clinical syndromes and possible mechanism. In: Pancheri P, Zichella L (eds) *Biorhythms and stress in the physiopathology of reproduction*. Hemisphere Publishing Co, Washington, DC, pp 1988; 293-317.
 30. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. *Diabetologia* 1985; 28: 485-93.
 31. Jong-pyo L, Hong-kwon K, Hye-jin S, Eun-hee K, Hee-dong C. Effects of somatostatin analogue pretreatment on ovarian response to ovulation induction in patients with polycystic ovarian syndrome. 2000; 43(3): 423-30.
 32. David TV, Valerie SR, William SE, Dale WS, Scott WK, John EN. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in

- patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. *Fertil Steril* 2001; 75: 310-5.
33. Williams G. Management of non insulin-dependent diabetes mellitus. *Lancet* 1994; 343: 95-100.
34. Robert LB. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. *Am J Obstet Gynecol* 2000; 183: 1412-8.
35. Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese infertile women. *Fertil Steril* 1982; 38: 406-9.
36. Paswuali R, Antenucci D, Gasimirri F, Venturoli S, Paradisi R, Fabbri R, et al. Clinical and hormonal characteristics of obese and amenorrheic women before and after weight loss. *J Clin Endocrinol Me* tab 1989; 68: 173-9.
37. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod* 1998; 13: 1502-5.
38. Hollman M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese infertile women. *Hum Reprod* 1996; 11: 1884-91.
39. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod* 1995; 10: 2705-12.
-